LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Bio-Rad Laboratories Inc

Abierto

SectorSanidad

242.24 -0.33

Resumen

Variación precio

24h

Actual

Mínimo

233.2

Máximo

244.52

Métricas clave

By Trading Economics

Ingresos

780M

64M

Ventas

-82M

585M

BPA

2.54

Margen de beneficios

10.933

Empleados

7,700

EBITDA

75M

134M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+32.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-97M

6.4B

Apertura anterior

242.57

Cierre anterior

242.24

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Bio-Rad Laboratories Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 jun 2025, 23:49 UTC

Ganancias

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Ganancias

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Ganancias

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Adquisiciones, fusiones, absorciones

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Ganancias

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Charlas de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Ganancias

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Ganancias

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Bio-Rad Laboratories Inc previsión

Precio Objetivo

By TipRanks

32.05% repunte

Estimación a 12 Meses

Media 321.5 USD  32.05%

Máximo 381 USD

Mínimo 245 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Rad Laboratories Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

229.835 / 235.8095Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

154 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.